Overview of Resilar

Property	Description
Active ingredient	Dextromethorphan Hydrobromide
Form	Oral liquid (syrup/solution) or oral solid (tablet/capsule)
Pharmacological class	Antitussive (Cough Suppressant)
Common use	Temporary suppression of non-productive cough
Origin	Synthetic (Morphinan derivative)

Resilar is the trade name for a medicine containing Dextromethorphan Hydrobromide, which is officially classified as an antitussive compound used to provide symptomatic relief from the urge to cough. The drug entity is commercially positioned as a cough suppressant commonly available over-the-counter (OTC), underscoring its broad patient accessibility for minor respiratory symptoms. The active substance is a synthetic compound derived from the morphinan chemical class, a fact widely supported by pharmacological studies.

What Type of Medicine is Resilar?

Resilar is fundamentally an oral, centrally acting non-opioid antitussive medication. The Dextromethorphan Hydrobromide compound is clinically recognized for its ability to modulate activity in the dedicated cough center located in the brain's medulla. This mechanism allows the drug to elevate the body's cough threshold, thereby suppressing the frequency and intensity of coughing spells. This targeted central action clearly differentiates the product from peripherally acting agents or expectorants, offering a distinct, systemic approach to cough control.

Composition and Physical Form

The core composition involves Dextromethorphan Hydrobromide as the primary active ingredient, which is prepared for oral administration. The product is commonly manufactured in various dosage form(s), including palatable liquids, such as syrups and solutions, and oral solids, including tablets and capsules. The final identity of Resilar is either a single-entity preparation or a combination product, where the active ingredient is formulated with an aqueous base (for liquids) or appropriate solid excipients (for tablets/capsules). The general therapeutic purpose is exclusively the suppression of the involuntary cough impulse in a typical upper respiratory symptom scenario.

Regulatory References

What side effects are possible with Resilar?

Possible Side Effects and Safety Information

The safety profile for Dextromethorphan Hydrobromide (Resilar) is established in regulatory documents, classifying potential adverse events primarily by frequency and the body system affected. According to official labeling, many non-serious adverse reactions are classified as uncommon (occurring in fewer than 1 in 100 people), primarily involving the Gastrointestinal Disorders and Nervous System Disorders organ classes.

Officially Documented Adverse Reactions (Examples)

System Organ Class	Frequency Classification
Nervous System Disorders	Drowsiness, Dizziness (Uncommon)
Gastrointestinal Disorders	Nausea, Vomiting, Abdominal Discomfort (Uncommon)
Psychiatric / Immune Systems	Drug Dependence, Hypersensitivity Reactions (Frequency Unknown)

Documented Serious Safety Concerns

The regulatory label highlights several clinically important safety risks. The most serious concern involves the potential for Serotonin Syndrome, a potentially life-threatening condition associated with the concomitant use of other serotonergic agents, such as Monoamine Oxidase Inhibitors (MAOIs). Additionally, drug abuse, misuse, dependence, and withdrawal are classified as important identified risks. The label also documents the potential for toxicity in overdose, which may include cardiotoxicity, respiratory depression, and severe neurological events.

Population and Contextual Safety Notes

Specific caution is advised for certain patient populations, as stated in regulatory monographs. Patients with hepatic dysfunction are noted to require caution. Individuals identified as poor metabolizers of the CYP2D6 enzyme are at higher risk for exaggerated and prolonged effects, increasing the potential for toxic effects and Serotonin Syndrome. Furthermore, the risk of drug dependence is increased with prolonged use and in individuals with a history of substance misuse disorder.

Overdose and Emergency Response

Overdose with Resilar (Dextromethorphan Hydrobromide) may lead to severe, centrally-mediated manifestations. Officially documented signs of acute toxicity involve profound Central Nervous System (CNS) effects, including stupor, toxic psychosis, hyperexcitability, confusion, and hallucinations. Neurological signs such as ataxia (unsteady movements) and nystagmus (involuntary eye movements) are also recognized presentations listed in regulatory information.

The official overdose profile emphasizes the risk of severe, life-threatening outcomes. These complications include coma, seizures, and respiratory depression—a risk noted to be particularly severe in young children. A further documented risk, particularly with high-dose exposure, is the development of Serotonin Syndrome.

Government health authorities strictly mandate that any suspected overdose requires the patient to seek immediate medical attention. This means contacting emergency medical services or a certified Poison Control Center without delay. The regulatory basis for managing Dextromethorphan toxicity confirms that no specific antidote is known. Therefore, care administered by health professionals is defined as symptomatic and supportive treatment, involving critical monitoring of vital signs and potentially procedures like activated charcoal or breathing support.

Therapeutic Uses of Resilar

What Resilar Treats: Main Uses and Benefits

The therapeutic application of Resilar (Dextromethorphan Hydrobromide) is commonly used for managing symptoms related to bothersome coughing. Dextromethorphan may be part of symptomatic management for cough associated with the common cold, the flu, or other conditions. The medication is applied in clinical settings that involve acute or unstable symptom patterns.

It may be relevant for managing the non-productive cough—the persistent, dry, and irritating urge to cough that produces no phlegm or mucus. Resilar is commonly used to help with symptoms in conditions presenting with acute episodes, including those of minor upper respiratory tract infections, the common cold, and influenza.

Easing Symptoms That Disrupt Rest and Function

A relevant benefit may be that it helps address symptoms related to heightened physiological activity, particularly when symptoms become more noticeable. This assists with maintaining functional stability, and may be relevant for easing symptoms that interfere with daily functioning. This supportive relief is commonly used when short-term symptomatic assistance is needed.

Quick Fact: Symptomatic Support for Non-Productive Cough The medication is relevant for managing symptoms related to irritative states, supports patients during difficult episodes by easing the overall symptom load of a frequent, dry cough.

Regulatory References

NIH MedlinePlus overview

Eligibility and Restrictions for Use

Who Can and Cannot Use Resilar?

Eligibility for Resilar (Dextromethorphan Hydrobromide) is strictly defined by government regulatory documents, establishing absolute prohibitions and conditional use guidelines for specific populations.

Contraindications and Prohibited Populations

The medicine is contraindicated and must not be used by individuals with a known hypersensitivity to Dextromethorphan or any component in the formulation. Use is also absolutely prohibited in patients who are currently receiving or have discontinued therapy with a Monoamine Oxidase Inhibitor (MAOI) within the preceding 14 days.

Age and Condition Restrictions

Official labeling explicitly prohibits use in children younger than 4 years of age. The product is not intended for the management of a persistent or chronic cough (such as that associated with asthma or emphysema) or for a cough accompanied by excessive phlegm or mucus. A conditional restriction applies to patients with Phenylketonuria (PKU) if the specific formulation contains aspartame.

Use in Specialized Populations

Use requires special consideration and caution in patients with severe hepatic impairment or severe renal impairment. For pregnancy, use is restricted to situations where the potential benefit justifies the possible risk. Lactation use is generally not recommended, and alcohol-containing formulations should be avoided.

What should I know about interactions with other medicines?

Resilar (noscapine) is known to have clinically important interactions that primarily involve drug metabolism, which may alter the effects of co-administered medications.

Interactions with Oral Anticoagulants

The most significant documented interaction is with coumarin derivative anticoagulants, such as warfarin, acenocoumarol, and phenprocoumon. Noscapine can increase the anticoagulative effect of these medicines, leading to a potentially higher risk of bleeding.

Mechanistic Basis: Noscapine is an inhibitor of specific cytochrome P450 enzymes in the liver, namely CYP2C9 and CYP3A4. These enzymes are critical for breaking down coumarin derivatives. When noscapine inhibits these enzymes, the concentration of the anticoagulant in the body increases, which results in a greater blood-thinning effect, often measured as an increase in the International Normalized Ratio (INR).

Other Potential Interactions

Noscapine may also have additive effects when combined with substances that depress the central nervous system, such as alcohol or certain hypnotics and sedatives. This combination may enhance effects like drowsiness or loss of coordination. Although not a formal interaction, it is generally advised against combining noscapine with expectorants or mucolytics.

Mechanism of Action

How Resilar Works: Mechanism of Action

Central Modulation of the Medullary Neural Substrate

The core mechanism of Dextromethorphan Hydrobromide is exerted centrally through direct interaction with key receptors in the brainstem's medulla, the neural substrate responsible for regulating the cough reflex arc. The drug acts by engaging the Sigma-1 receptor (sigma1R) and, via its active metabolite, blocking the excitatory NMDA receptor. This molecular activity reduces the excitability of the cough-coordinating neural circuits.

Dampening Excitatory Neurotransmission and Reflex Sensitivity

By antagonizing the NMDA receptor and modulating serotonin signaling pathways, the drug reduces overall excitatory neurotransmission within the reflex arc. This central action results in an elevated cough threshold, meaning the medullary center exhibits reduced sensitivity to afferent inputs. The physiological outcome is a decreased requirement for excitatory input to initiate the reflex response.

Dosage and Administration Information

Resilar, which contains Dextromethorphan Hydrobromide, is administered exclusively through the oral route, available in both liquid and solid dosage forms for immediate-release (IR) or extended-release (ER) use. The official administration guidelines define the permitted dose amounts and the frequency with which the medicine may be taken, establishing a strict framework for use.

For immediate-release forms, the standard adult regimen for individuals 12 years of age and older is generally described as 10 mg to 20 mg taken every four hours, or an alternative 30 mg dose administered every six to eight hours. Extended-release forms have a defined use pattern of 60 mg taken every 12 hours. All regimens are subject to a definitive ceiling, as the total intake must not exceed 120 mg in any 24-hour period.

When administering liquid preparations, a calibrated measuring device is required to ensure the accuracy of the dose volume, consistent with official procedural standards. The medicine is intended for temporary use only and should not be administered for a period exceeding seven days. Furthermore, while the medicine may be taken with or without food, the intervals between doses must be strictly observed. Dosage patterns for children aged six to twelve years are distinct and reduced compared to the adult regimen, reflecting specific age-based requirements found in regulatory documentation.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Resilar

Evidence for Use in Acute Non-Productive Cough

The official research base for Dextromethorphan Hydrobromide (Resilar) consists primarily of short-term, controlled clinical studies, known as randomized controlled trials (RCTs). These are formal research studies where participants with cough related to a common cold or minor upper respiratory infection are randomly assigned to receive either the medicine or an inactive substance.

In these trials, researchers examined outcomes related to physical discomfort by using specialized equipment to measure the total number of coughs (an objective measure) and monitored patient-reported outcomes describing perceived discomfort. When researchers analyzed the groups, some trials monitored different patterns in objective cough counts between the group receiving the medicine and the placebo group, particularly during the initial hours of observation. However, regulatory reviews often note that a placebo response is a recognized factor in cough research. Furthermore, reported outcomes were short-term and sometimes did not align consistently when comparing the objective cough counts with the subjective relief reported by patients.

Length of Studies and Follow-up Durations

The typical follow-up durations were limited, meaning the efficacy trials primarily assessed responses over defined time intervals that ranged from just a few hours after a single dose up to a maximum of four days for multi-dose regimens. Consequently, research provides insight into short-term changes during periods of increased symptom activity, but long-term effects are not fully established. There is limited information for long-term outcomes, as existing studies provide limited insight into whether any observed patterns persist beyond the acute, short-term episode.

Research Limitations and Areas of Uncertainty

Key limitations are frequently cited in systematic reviews and scientific assessments. One major factor is the recognized role of the placebo effect in cough research, which studies indicate can make it challenging to quantify the difference between the compound and placebo. Data for efficacy also remain insufficient for children under 6 years of age, and specific outcome patterns in this very young subgroup are not well-established by current controlled trials. Comparative evidence is also sometimes lacking; most research explores the compound against a placebo rather than against other available medications.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Resilar (FAQ)

Q: Is Resilar the same type of medicine as [similar common drug name]?

According to official product information, the active ingredient in Resilar, Dextromethorphan, is classified as a non-opioid antitussive or cough suppressant. This means it works centrally by acting on the cough center in the brain to elevate the cough threshold. This mechanism is distinct from other classes of agents, such as expectorants or decongestants.

Q: Can Resilar be taken by people with kidney issues?

Official labeling indicates that use is generally not advised for individuals with severe kidney disease. Since the drug and its metabolites are excreted through the kidneys, caution is advised. Specific consideration is warranted for any degree of renal impairment.

Q: How does the drug Resilar affect [broad organ system, e.g., the liver]?

The active ingredient is metabolized primarily in the liver by an enzyme known as CYP2D6. Official safety notes recommend caution for patients with hepatic impairment. For individuals with severe liver disease, official information indicates that use is generally not advised.

Q: What should I know about taking Resilar with other prescription medicines?

Official warnings highlight that Resilar is absolutely contraindicated with Monoamine Oxidase (MAO) inhibitors. Taking it with other serotonergic agents (medications that affect serotonin) may also lead to the risk of a serious condition called Serotonin Syndrome. The potential for interactions is also noted with medications that inhibit the CYP2D6 enzyme or with other drugs that cause Central Nervous System (CNS) depression.

Q: Is Resilar safe for people with diabetes?

The active ingredient, Dextromethorphan, does not have specific contraindications for diabetes. Many commercial formulations are available that are labeled as sugar-free and alcohol-free, making them relevant options for individuals managing blood sugar. Studies have not generally shown a correlation between the drug's use and changes in hemoglobin A1c (a key diabetes measure).

Q: Does Resilar cause weight gain, according to regulatory information?

Regulatory product information lists changes in weight as a documented, though less common, potential adverse effect. Specifically, rapid weight gain or unusual weight gain/loss has been noted in postmarketing reports. This is not listed among the most common adverse events.

Q: How quickly should I expect Resilar to start working?

While the precise moment of symptom relief is not listed, pharmacokinetic data, which describe how the body handles the drug, indicates when the drug is absorbed. For immediate-release formulations, pharmacokinetic data suggests the active compound may reach its peak concentration in the blood within approximately 2.5 hours.

Q: Does Resilar interact with caffeine?

Regulatory safety reviews do not list a formal contraindication for using the drug with caffeine. However, the combination may lead to intensified nervous system side effects, such as dizziness or nervousness. It could also mask the drowsiness effect that the medicine can sometimes cause.

Q: Is Resilar considered a controlled substance?

No, Dextromethorphan is not classified as a controlled substance under the federal Controlled Substances Act in the United States. It is widely available over-the-counter for cough relief. Regulatory notes indicate that some state or local authorities have implemented restrictions on the sale of products containing Dextromethorphan to individuals under 18 years of age.

Q: Why do official documents mention restrictions for people with heart conditions using Resilar?

The concern is typically directed at combination products that contain decongestants, such as phenylephrine. These added ingredients may lead to an increase in heart rate and blood pressure, which is a known risk for people with certain heart conditions. Dextromethorphan, when used alone, is not generally contraindicated in common heart conditions.

Q: How is Resilar eliminated from the body?

According to official pharmacological information, the active substance is metabolized in the liver into its active forms. These compounds, along with any unchanged drug, are then primarily excreted in the urine.

Q: Is Resilar safe to take with common pain relievers like ibuprofen?

Official drug interaction checkers indicate that there is no specific interaction noted between Dextromethorphan and common Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) such as ibuprofen. The focus of safety warnings typically relates to other categories of prescription medicines.

Q: What kind of monitoring is needed while taking Resilar?

For routine, temporary use, no specific external monitoring is typically required. However, in certain contexts where the medicine is combined with interacting prescription drugs, monitoring such as blood tests or checking blood pressure may be mentioned in clinical literature.

Q: Are there any specific lifestyle changes recommended when starting Resilar?

The main lifestyle caution highlighted in the safety information is the avoidance of alcohol. Combining the medicine with alcohol may lead to enhanced Central Nervous System (CNS) depressant effects, which could increase drowsiness.

Q: What does the FDA classification mean for Resilar?

The classification means that the FDA has approved the active ingredient, Dextromethorphan, as a Human Over-the-Counter (OTC) Drug. This designation reflects the regulatory determination that the medicine is generally recognized as safe and effective for temporary use without needing a prescription when all label directions are followed.

Q: Does Resilar have any known effects on blood pressure?

Therapeutic use of Dextromethorphan alone is generally not associated with changes in blood pressure. However, certain combination products that include nasal decongestants may cause an increase in blood pressure.

Q: Are there any common misunderstandings about what Resilar is designed to do?

A common misconception relates to its classification: it is a non-opioid antitussive that suppresses the urge to cough by acting on the brain. This function is distinctly different from expectorants, which help loosen mucus, or certain opioids, which are used for pain relief.

Q: Can men and women use Resilar equally, or are there gender-specific warnings?

According to official regulatory documents and safety profiles, there are no specific dosage adjustments or unique restrictions based on the patient's gender. Use is determined primarily by age, weight, and existing medical conditions.

Q: Does the time of day matter when taking Resilar?

The official dosing instructions are based on time intervals, such as every four or twelve hours, rather than a specific time of day. However, because the drug can cause drowsiness, some individuals may choose to take it closer to bedtime to minimize daytime sedation.

Q: What are the signs that Resilar may not be working?

Regulatory warnings describe situations where the drug should be stopped and professional guidance sought, such as if the cough lasts for more than 7 days or if it returns. Guidance is also recommended if the cough is accompanied by fever, rash, or a persistent headache.

How should Resilar be stored and disposed of?

How to Store and Dispose of Resilar?

Storing and handling Resilar must strictly follow official requirements to maintain the drug’s stability and potency.

Before Reconstitution (Unopened Vial):

Temperature: Store in a refrigerator between 2 C to 8 C (36 F to 46 F). Do not freeze.
Protection: Keep the vial in its original carton to protect the product from light until the time of use.

After Reconstitution (Prepared Solution):

Stability: The reconstituted solution has limited stability. It must be used within a short, defined period (e.g., within 60 minutes) if kept at room temperature. If refrigerated, the use period is slightly extended (e.g., up to 4 hours).
Handling: The vial must be gently swirled during preparation; do not shake. Any unused portion of the prepared solution must be discarded.

Disposal:

Unused, expired, or partially used Resilar and related materials (vials, syringes) must be disposed of according to standard local or national regulations for pharmaceutical waste. The medicine must be kept out of the reach of children.

Resilar